FIRST WAVE BIOPHARMA (FWBI)

First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients

Paper highlights findings on impact of a gluten-containing diet on serologic status in celiac disease

First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference

BOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a...

First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference

Poster presentations to highlight new quantitative and serologic diagnostic methods for Celiac Disease detection and determination of intestinal mucosal...

Why Is Fisker (FSR) Stock Down 41% Today?

Fisker stock is falling hard on Thursday as FSR investors react to reports that the EV company is preparing to file for bankruptcy.

Why Is Spruce Biosciences (SPRB) Stock Down 78% Today?

Spruce Biosciences stock is falling hard on Thursday as investors in SPRB shares react to the latest clinical trial data reported.

Why Is First Wave BioPharma (FWBI) Stock Up Today?

First Wave BioPharma stock is up on Thursday as FWBI investors celebrate the company completing its business combination with ImmunogenX.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of all the biggest pre-market stock movers worth watching on Thursday morning!

First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline

Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease James Sapirstein, Chairman and Chief Executive...

First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth Conference

BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a...

First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024

BOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a...

First Wave BioPharma to Present at the DealFlow MicroCap Conference

BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a...

First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico

BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a...

First Wave BioPharma files to sell 1.76M for holders (NASDAQ:FWBI)

First Wave BioPharma files prospectus for the resale of over 1.76M shares by selling stockholders.

Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI

First Wave expecting "significant" investments if ImmunogenX deal closes (NASDAQ:FWBI)

First Wave BioPharma is expecting "significant" investments if and when its proposed deal to merge with celiac disease drug developer ImmunogenX. Read more here.

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024

Multiple clinical and development milestones anticipated in 2024, including initiation of Phase 3 clinical trial investigating latiglutenase in celiac...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time to dive into the biggest pre-market stock movers with all of the latest coverage worth reading about on Wednesday morning!

First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced

BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (“First Wave BioPharma” or the “Company”) (NASDAQ: FWBI), a clinical-stage...

Why Is First Wave Biopharma (FWBI) Stock Up 148% Today?

FWBI stock is soaring after the company tentatively agreed to sell its its potential treatment for inflammatory bowel disease (IBD).